These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4209275)

  • 1. Hypothalamic releasing factors and Parkinson disease.
    Chase TN; Woods AC; Lipton MA; Morris CE
    Arch Neurol; 1974 Jul; 31(1):55-6. PubMed ID: 4209275
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.
    Castensson S; Sievertsson H; Lindeke B; Sum CY
    FEBS Lett; 1974 Aug; 44(1):101-5. PubMed ID: 4212370
    [No Abstract]   [Full Text] [Related]  

  • 3. Melanocyte-stimulating hormone and parkinsonism: the role of hypothalamic releasing factors.
    Sandler M; Goodwin BL; Leask BG; Ruthven CR
    Lancet; 1973 Mar; 1(7803):612. PubMed ID: 4120682
    [No Abstract]   [Full Text] [Related]  

  • 4. Melanocyte-stimulating hormone and the hypothalamic hormone which inhibits its release.
    Kastin AJ; Barbeau A; Ehrensing RH; Plotnikoff NP; Schally AV
    Adv Neurol; 1974; 5():225-9. PubMed ID: 4216256
    [No Abstract]   [Full Text] [Related]  

  • 5. Inactivation of melanocyte-stimulating hormone release-inhibiting factor by a manganese-stimulated bovine brain aminopeptidase.
    Simmons WH; Brecher AS
    J Biol Chem; 1973 Aug; 248(16):5780-4. PubMed ID: 4353274
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Eur Neurol; 1974; 12(5-6):360-8. PubMed ID: 4614981
    [No Abstract]   [Full Text] [Related]  

  • 7. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP; De Carolis AS; Longo VG
    Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044
    [No Abstract]   [Full Text] [Related]  

  • 8. 13C nuclear magnetic resonance studies of the conformation of the X-pro bond in the oligopeptide hormones, thyrotropin-releasing hormone, luteinizing hormone-releasing factor, angiotensin and melanocyte-stimulating hormone release-inhibiting factor.
    Deslauriers R; Walter R; Smith IC
    Biochem Biophys Res Commun; 1973 Jul; 53(1):244-50. PubMed ID: 4354931
    [No Abstract]   [Full Text] [Related]  

  • 9. Melanocyte-stimulating hormone-release inhibiting hormone as a antidepressant. A pilot study.
    Ehrensing RH; Kastin AJ
    Arch Gen Psychiatry; 1974 Jan; 30(1):63-5. PubMed ID: 4587068
    [No Abstract]   [Full Text] [Related]  

  • 10. Behavioral effects of thyrotropin releasing hormone in animals and man: a generic hypothesis.
    Prange AJ; Wilson IC
    Psychopharmacol Bull; 1975 Jan; 11(1):22-4. PubMed ID: 804704
    [No Abstract]   [Full Text] [Related]  

  • 11. Carbon-13 NMR studies of peptide hormones and their components.
    Smith IC; Deslauriers R; Saitô H; Walter R; Garrigou-Lagrange C; McGregor H; Sarantakis D
    Ann N Y Acad Sci; 1973 Dec; 222():597-627. PubMed ID: 4361873
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: Lithium and M.R.I.H. in tardive dyskinesia.
    Ehrensing RH
    Lancet; 1974 Dec; 2(7894):1459-60. PubMed ID: 4140382
    [No Abstract]   [Full Text] [Related]  

  • 13. Isolation and structure of hypothalamic MSH release-inhibition hormone.
    Nair RM; Kastin AJ; Schally AV
    Biochem Biophys Res Commun; 1971 Jun; 43(6):1376-81. PubMed ID: 4398196
    [No Abstract]   [Full Text] [Related]  

  • 14. MSH-release inhibiting factors: recent studies.
    Kastin AJ; Plotnikoff NP; Viosca S; Anderson MS; Schally AV
    Yale J Biol Med; 1973 Dec; 46(5):617-22. PubMed ID: 4591788
    [No Abstract]   [Full Text] [Related]  

  • 15. General activity in intact and hypophysectomized rats after administration of melanocyte-stimulating hormone (MSH), melatonin, and PRO-LEU-GLY-NH 2 .
    Kastin AJ; Miller MC; Ferrell L; Schally AV
    Physiol Behav; 1973 Feb; 10(2):399-401. PubMed ID: 4575310
    [No Abstract]   [Full Text] [Related]  

  • 16. L-prolyl-L-leucyl-glycinamide (PLG): influences on locomotor and stereotyped behavior of cats.
    North RB; Harik SI; Snyder SH
    Brain Res; 1973 Dec; 63():435-9. PubMed ID: 4797171
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chemistry of the "releasing" hormones. History and latest developments].
    Boler J
    Tidsskr Nor Laegeforen; 1972 Nov; 92(32):2154-60. PubMed ID: 4632739
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemistry of the hypothalamic releasing factors--studies on structure-function relationships.
    Vale W; Grant G; Guillemin R
    Front Neuroendocrinol; 1973; 0(0):375-413. PubMed ID: 4369859
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemistry of releasing hormones.
    Sandow J
    J Endocrinol; 1973 Aug; 58(2):32-3. PubMed ID: 4199267
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: Intravenous thyrotrophin-releasing hormone in Parkinson's disease.
    McCaul JA; Cassell KJ; Stern GM
    Lancet; 1974 Apr; 1(7860):735. PubMed ID: 4132453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.